PowerUp Acquisition (PWUP) and Aspire Biopharma agreed to merge with the transaction valuing Aspire at about $316 million before any new capital is added from an investment.
The boards approved the transaction, the companies said Tuesday in a statement. Aspire's shareholders will own more than a majority of the merged entity, and the combined company will be named Aspire Biopharma Holdings and is expected to be listed on Nasdaq under the ASPH ticker symbol.
The transaction is expected to close at the end of Q4 or early in Q1, subject to certain conditions, including regulatory and stockholder approvals.
Price: 11.26, Change: +0.03, Percent Change: +0.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.